Sanofi-Aventis reported a strong Q2 2009. Sales were up 11% from a year earlier to €7.44B, and profits rose 4.9% to €1.06 from a year ago.
Sanofi-Aventis reported a 2.5% increase in sales from a year ago, as well as a 16.8% increase in adjusted earnings.
Sanofi-Aventis finished purchasing 94 percent of Czech drugmaker Zentiva, up from its previous offer of $1.8 billion. The company has stated it intends to delist the firm.
Sanofi-Aventis bought the Czech generics manufacturer Zentiva for $1.8 billion euros (US$2.6 billion). The company already held a 24.9 stake in Zentiva since March of 2006